Jump to navigation Jump to search
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass285.28 g/mol
3D model (JSmol)

WikiDoc Resources for Nifuratel


Most recent articles on Nifuratel

Most cited articles on Nifuratel

Review articles on Nifuratel

Articles on Nifuratel in N Eng J Med, Lancet, BMJ


Powerpoint slides on Nifuratel

Images of Nifuratel

Photos of Nifuratel

Podcasts & MP3s on Nifuratel

Videos on Nifuratel

Evidence Based Medicine

Cochrane Collaboration on Nifuratel

Bandolier on Nifuratel

TRIP on Nifuratel

Clinical Trials

Ongoing Trials on Nifuratel at Clinical

Trial results on Nifuratel

Clinical Trials on Nifuratel at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Nifuratel

NICE Guidance on Nifuratel


FDA on Nifuratel

CDC on Nifuratel


Books on Nifuratel


Nifuratel in the news

Be alerted to news on Nifuratel

News trends on Nifuratel


Blogs on Nifuratel


Definitions of Nifuratel

Patient Resources / Community

Patient resources on Nifuratel

Discussion groups on Nifuratel

Patient Handouts on Nifuratel

Directions to Hospitals Treating Nifuratel

Risk calculators and risk factors for Nifuratel

Healthcare Provider Resources

Symptoms of Nifuratel

Causes & Risk Factors for Nifuratel

Diagnostic studies for Nifuratel

Treatment of Nifuratel

Continuing Medical Education (CME)

CME Programs on Nifuratel


Nifuratel en Espanol

Nifuratel en Francais


Nifuratel in the Marketplace

Patents on Nifuratel

Experimental / Informatics

List of terms related to Nifuratel

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Nifuratel (brand name Macmiror, or—in combination with nystatinMacmiror Complex) is a drug used in gynecology. It is a local antiprotozoal and antifungal agent that may also be given orally. Nifuratel is not approved for use in the United States.

Nifuratel appears to have a broad antibacterial spectrum of action and is effective against Chlamydia trachomatis and Mycoplasma spp. as well as fungal infections from Candida spp.[1]

Taken orally, or as a vaginal pessary, it is used in the treatment of a wide range of infections of the genito-urinary tract, especially if there is no accurate diagnosis available. For example it may be used in the treatment of women exhibiting vaginal discharge where there is uncertainty as to whether the cause is Trichomonas vaginalis or Candida strains such as Candida albicans.

Side effects appear to be minimal or non-existent and it has a safe toxicological profile.[2]


  1. Treatment of candidal urinary tract infection with nifuratel. R N Grüneberg, A Leakey
  2. Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections. A review. Werner Mendling, Federico Mailland Klinik für Frauenheilkunde und Geburtshilfe, Klinikum Am Urban, Berlin, Germany.